Skip to main content
TYRA
NASDAQ Life Sciences

Tyra Biosciences Reports 79% ORR in Phase 2 SURF302 for Oral Dabogratinib in Bladder Cancer

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$22.22
Mkt Cap
$1.595B
52W Low
$11.703
52W High
$40.65
52W Position info
90% above low
Off High info
45% below high
Rel. Volume info
1.5× avg
Market data snapshot near publication time

TYRA sits 90% above its 52-week low of $11.703.

Summary

Tyra Biosciences reported positive Phase 2 SURF302 data for oral dabogratinib in bladder cancer, with 79% ORR at 60 mg QD and a clean safety profile, supporting a planned registrational adjuvant study in 2027.

Updates

  1. · Seeking Alpha — Shares dropped more than 20% in premarket trading after the data release.


Key Events · Product Development and Regulatory · TYRA

  • Phase 2 SURF302 Efficacy Results

    79% ORR (11/14) at 60 mg QD and 67% ORR (8/12) at 50 mg QD in FGFR3-altered LG IR NMIBC; 64% best overall complete response rate at 60 mg.

  • Favorable Safety Profile

    No Grade 4/5 TEAEs, no dose reductions or treatment-related discontinuations at 60 mg QD; Grade 3 treatment-related AEs in only 2 of 44 participants (4.5%).

  • Dose Selection and Registrational Path

    Exposure-response analysis supports 60 mg QD for adjuvant setting; company plans to engage health authorities on Phase 3 design and initiate registrational adjuvant study in 2027.

  • SURF303 and BEACH301 Updates

    First SURF303 patient (LG UTUC) achieved complete response at 3-month assessment; BEACH301 cleared fifth dose level with no safety signals in pediatric achondroplasia cohort.


Analysis · TYRA · Life Sciences

Tyra Biosciences announced initial Phase 2 SURF302 results showing a 79% overall response rate (11/14) at the 60 mg once-daily dose of oral dabogratinib in FGFR3-altered low-grade intermediate-risk non-muscle invasive bladder cancer. The safety profile was clean — no Grade 4/5 adverse events, no dose reductions or treatment-related discontinuations at the selected dose. This is clinical proof of concept for selective oral FGFR3 inhibition and de-risks the planned registrational adjuvant study expected to start in 2027. The company also reported a complete response in the first SURF303 patient and cleared the fifth dose level in the pediatric BEACH301 study. Against a $1.6 billion market cap, positive Phase 2 data in a >$5 billion market opportunity is a meaningful value inflection.

How filings like this one have moved

In the 30 days to Nov 9, 2026, 47.1% of the 1533 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, TYRA was trading at $22.22 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $11.70 to $40.65. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

TYRA - Latest Insights

TYRA
Sep 17, 2026, 4:32 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $24.43
Real-time Price: $21.15 info
Change: -$3.28 (-13%) info
Market Cap: $1.454B info
TYRA
Sep 14, 2026, 7:12 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $25.20
Real-time Price: $21.15 info
Change: -$4.05 (-16%) info
Market Cap: $1.454B info
TYRA
Sep 14, 2026, 7:09 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $25.20
Real-time Price: $21.15 info
Change: -$4.05 (-16%) info
Market Cap: $1.454B info
TYRA
Sep 14, 2026, 6:45 AM EDT
Source: PR Newswire
Importance Score:
8
Price at Filing: $21.70
Real-time Price: $21.15 info
Change: -$0.550 (-3%) info
Market Cap: $1.454B info
TYRA
Sep 14, 2026, 6:33 AM EDT
Filing Type: FWP
Importance Score:
7
Price at Filing: $21.70
Real-time Price: $21.15 info
Change: -$0.550 (-3%) info
Market Cap: $1.454B info